tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NBIX Stock Latest News

Neurocrine price target raised to $168 from $163 at Morgan Stanley
The FlyNeurocrine price target raised to $168 from $163 at Morgan Stanley
2h ago
NBIX
Positive Outlook for Neurocrine Biosciences Amidst Strong Prescription Growth and Strategic Positioning
PremiumRatings
Positive Outlook for Neurocrine Biosciences Amidst Strong Prescription Growth and Strategic Positioning
3h ago
NBIX
Neurocrine presents new data from Phase 3, open-label KINECT 4 study
PremiumThe Fly
Neurocrine presents new data from Phase 3, open-label KINECT 4 study
3d ago
NBIX
Neurocrine price target raised to $195 from $188 at UBS
PremiumThe Fly
Neurocrine price target raised to $195 from $188 at UBS
11d ago
NBIX
Neurocrine presents new data from KINECT-HD2 study of ingrezza
PremiumThe Fly
Neurocrine presents new data from KINECT-HD2 study of ingrezza
14d ago
NBIX
Neurocrine’s ingrezza shows efficacy in tardive dyskinesia
PremiumThe FlyNeurocrine’s ingrezza shows efficacy in tardive dyskinesia
27d ago
NBIX
Promising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine Biosciences
Premium
Ratings
Promising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine Biosciences
27d ago
NBIX
Neurocrine price target raised to $169 from $160 at Jefferies
Premium
The Fly
Neurocrine price target raised to $169 from $160 at Jefferies
28d ago
NBIX
Neurocrine announces Phase 2 SAVITRI met primary efficacy endpoint
PremiumThe Fly
Neurocrine announces Phase 2 SAVITRI met primary efficacy endpoint
28d ago
NBIX
Neurocrine’s Osavampator Shows Promising Phase 2 Results, Boosting Buy Rating and Stock Price Target
PremiumRatings
Neurocrine’s Osavampator Shows Promising Phase 2 Results, Boosting Buy Rating and Stock Price Target
28d ago
NBIX
Promising Potential of Neurocrine’s Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman
PremiumRatings
Promising Potential of Neurocrine’s Osavampator in Treating Major Depressive Disorder: A Buy Recommendation by Sean Laaman
29d ago
NBIX
Neurocrine price target raised to $149 from $144 at RBC Capital
PremiumThe Fly
Neurocrine price target raised to $149 from $144 at RBC Capital
2M ago
NBIX
Neurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
PremiumRatingsNeurocrine’s Strong Market Performance and Promising Pipeline Justify Buy Rating
2M ago
NBIX
Promising Growth and Strategic Positioning Drive Buy Rating for Neurocrine
Premium
Ratings
Promising Growth and Strategic Positioning Drive Buy Rating for Neurocrine
3M ago
NBIX
Neurocrine Biosciences Advances Schizophrenia Treatment with Phase 3 Study
Premium
Company Announcements
Neurocrine Biosciences Advances Schizophrenia Treatment with Phase 3 Study
3M ago
NBIX
Neurocrine Biosciences Advances Phase 3 Study on Valbenazine for Cerebral Palsy Dyskinesia
PremiumCompany Announcements
Neurocrine Biosciences Advances Phase 3 Study on Valbenazine for Cerebral Palsy Dyskinesia
3M ago
NBIX
Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors
PremiumCompany Announcements
Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors
3M ago
NBIX
Neurocrine’s Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
PremiumRatings
Neurocrine’s Promising Financial Outlook: Strong Crenessity Performance and Strategic Ingrezza Adjustments Drive Buy Rating
3M ago
NBIX
Neurocrine price target raised to $175 from $165 at Guggenheim
PremiumThe Fly
Neurocrine price target raised to $175 from $165 at Guggenheim
3M ago
NBIX
Neurocrine Biosciences’ Earnings Call Highlights Growth
PremiumCompany AnnouncementsNeurocrine Biosciences’ Earnings Call Highlights Growth
3M ago
NBIX
Neurocrine price target raised to $175 from $154 at Piper Sandler
Premium
The Fly
Neurocrine price target raised to $175 from $154 at Piper Sandler
3M ago
NBIX
Neurocrine price target raised to $186 from $180 at Baird
Premium
The Fly
Neurocrine price target raised to $186 from $180 at Baird
3M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >